Search For "drug eluting stent"
Understanding Coronary Artery Disease and the Role of Drug-Eluting Stents
Updated : 1 week, 3 days ago IST
Bangalore (Karnataka) [India], February 16: Coronary Artery Disease (CAD) is one of the most common heart conditions seen in India today. According to Dr Anand R Shenoy, Senior Interventional Cardiologist, Manipal Hospital, Old Airport Road, Bangalore, CAD develops when the arteries supplyin
Read More
SMT's Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across
Updated : 4 months, 4 weeks ago IST
Mumbai (Maharashtra) [India], October 29: Sahajanand Medical Technologies (SMT) announced significant new findings from four landmark clinical studies, namely TUXEDO II, Multivessel TALENT, Cruz Senior Study, and the SFlex Netherlands Registry, presented at the TCT 2025 conference. The colle
Read More
Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz's Safet
Updated : 5 months, 3 weeks ago IST
Mumbai (Maharashtra) [India], September 15: Sahajanand Medical Technologies (SMT), a medical devices company with a portfolio of technologically advanced medical devices across vascular and structural heart intervention, announced positive 3-year results from the FIRE Trial, presented at ESC
Read More
SMT Gets TGA Australia Approval for Supraflex Cruz
Updated : 1 year, 6 months ago IST
Mumbai (Maharashtra) [India], September 27: SMT (Sahajanand Medical Technologies), a global leader in innovative medical devices, proudly announces that its flagship drug-eluting stent (DES), Supraflex Cruz™, has received approval from the Therapeutic Goods Administration (TGA), Austra
Read More
SMT Announces Completion of Patient Enrolment for TUXEDO-2 Trial
Updated : 1 year, 7 months ago IST
Mumbai (Maharashtra) [India], August 16: SMT (Sahajanand Medical Technologies), a global leader in innovative medical devices, proudly announces the completion of patient enrolment for the Tuxedo 2 clinical trial in India. This landmark trial aims to evaluate the efficacy and safety of Supra
Read More
Terumo India Advances Treatment Options for Heart Disease with the Launch
Updated : 2 years, 3 months ago IST
New Delhi [India], December 18: Terumo India, the Indian arm of Japan based Terumo Corporation (TSE: 4543), a global leader in medical technology, recently announced the launch of Ultimaster Nagomi™, a Drug-Eluting Stent intended for use in the treatment of coronary artery disease.<
Read More
MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTI
Updated : 2 years, 6 months ago IST
Geneva [Switzerland], September 15: MedAlliance has announced enrollment of over 1,660 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now half way towards a planned 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel siroli
Read More
MedAlliance announces enrollment of First Patient in SELUTION SLR LOVE-DEB
Updated : 2 years, 6 months ago IST
Geneva [Switzerland], September 6: The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease treated with SELUTION SLR™. This is a trial initiated by physicians at the Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, which i
Read More
Over 1,000 patients enrolled in Landmark SELUTION DeNovo Study
Updated : 3 years ago IST
Geneva [Switzerland], March 15 (ANI/PRNewswire): MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3,326 patients. SELUTION DeNovo compares the treatment st
Read More
First patient enrolled in SELUTION SLR IDE BTK Study
Updated : 3 years, 9 months ago IST
Leipzig [Germany], June 8 (ANI/PRNewswire): The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial involving SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, just one week after receiving IDE approval.
Read More
Much awaited, much needed: TRANSFORM II Randomized Controlled Trial by Fon
Updated : 4 years, 1 month ago IST
Milano (Italy) [India], January 28 (ANI/PR Newswire): FONDAZIONE Ricerca e Innovazione Cardiovascolare, Milano, focused on cardiovascular research, reports the first patient enrolment of the TRANSFORM II Randomized Controlled Trial (Sirolimus-coated Balloon Versus Drug-eluting Stent in Nativ
Read More
MedAlliance announces first patient enrolled in the 3,300 Patient Landmark
Updated : 4 years, 6 months ago IST
Geneva [Switzerland], September 1 (ANI/PRNewswire): MedAlliance is pleased to announce the enrollment of the first patient in the ground-breaking coronary randomized controlled study "SELUTION DeNovo". This study utilizes SELUTION SLR™, a novel sirolimus drug-eluting balloon [DEB], ver
Read More